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Abstract:  
Introduction :  The intravesical instillation of mitomycin C immediately following surgery 
for non-muscle invasive bladder cancer has been shown to be efficacious in reducing 
cancer recurrence. As a result, the American Urological Association adopted guidelines 
for non-muscle invasive bladder cancer care to support its use in low to intermediate risk 
patients.  Despite this, urologists’ use of this drug following transurethral resection of a 
bladder tumor (TURBT) has been reported as low as 5% or less.  Our study objective 
was to better understand the barriers urologists experience in using mitomycin C. 
Methods : Semi-structured interviews were conducted with 13 practicing urologists at 4 
geographically distinct practice locations throughout Indiana between 2017 and 2018.  
Cognitive task analysis was used to explore factors that influenced their clinician 
decision-making about Mitomycin C use following TURBT in specific patient cases. 
Interview transcripts were coded and analyzed using immersion/crystallization to identify 
emergent themes.  
Results :  The median age of the urologists interviewed was 44 (IQR 40-48). Eighty-five 
percent were male. Approximately 30% had completed urologic fellowship training; 62% 
were in private practice.  Three major themes related to the use of mitomycin C 
emerged: cumbersome workflow processes, urologists’ fears of side effects, and issues 
of identifying patients most likely to benefit.  
Conclusion : Workflow, fear, and value are key factors and also represent complexities 
of translating efficacy into effectiveness for a drug with known benefits to patients. Areas 
of potential intervention development to improve the use of mitomycin C to reduce 
recurrence of bladder cancer are suggested.  Alternatives such as gemcitabine may also 


















 The treatment and follow-up care for non-muscle invasive bladder cancer 
(NMIBC) is particularly challenging due to frequent recurrences, the burden of 
surveillance for patients who endure repeated invasive procedures, economic costs of 
lifelong follow-up, and potential for progression into more aggressive muscle-invasive 
disease.  Notwithstanding, the challenges in managing NMIBC, randomized clinical 
trials supporting the use of intraoperative intravesical chemotherapy following 
transurethral resection of bladder tumors (TURBT) do exist. 1 Thirteen trials have 
demonstrated a reduction in recurrence of NIMBC by using intraoperative intravesical 
chemotherapy, 2-4 that when pooled together demonstrated an absolute risk reduction 
of 12% in those who received the therapy.5  
 Research to date suggests that utilization of intraoperative intravesical 
chemotherapy ranges from 3.2% to only 38% of TURBT cases.6,7 Previous attempts to 
understand barriers to utilization have been methodologically incomplete.8-10 Without 
knowing more about the decisions to use, or not use the treatment, interventions for 
improvement would be difficult, if not impossible, to craft successfully. Given the 
knowledge gap, we sought to understand urologists’ reasons for use and underuse of 



















Sampling and number of planned interviews.  
 Urologists were identified from the membership directory of the Indiana Urologic 
Association, Inc. (IUA).  Invitations to participate in the study were sent by mail to all 
active members with detailed contact information on how to respond if interested by 
either phone and/or email.  Due to a lack of response from this method, convenience-
sampling methods were then used. We strategically contacted urology practices in 4 
distinct geographic regions of the state by contacting a physician at each representative 
practice.   
 Data collection and analysis for this exploratory study were based on principles 
of cognitive task analysis (CTA),11 interview and qualitative analysis techniques 
designed to aid experienced practitioners in describing aspects of cognitive work that are 
often difficult to articulate. CTA techniques ground the interview in lived experiences to 
increase the accuracy and richness of recall. 12,13   Using this approach, we interviewed 
13 urologists at 4 locations representing multiple regions within Indiana. This is a typical 
number of interviews for exploratory CTA, in which the objective is to identify factors 
influencing a decision process, providing foundational findings that can be used to frame 
the problem, inform interventions, and inspire future research 12,13. 
 The interview approach chosen for this study included face-to-face semi-
structured interviews, leveraging two CTA interview techniques. 12  The task diagram 
was used at the beginning of each interview to obtain an overview of the task and 
workflow from the interviewee’s perspective. 13  The critical decision method was used to 
obtain specific examples and explore decision making context.  CTA methods have been 
















recently have been tailored for use in health care research.14  The interview guide is 
provided in Appendix 1. 
Interview Methods 
Task Diagram 
 The task diagram interview provides a framework to aid the interviewer in eliciting 
the major steps required to complete a task and highlighting for further examination 
those that are most cognitively complex 12.  
Critical Decision Method 
 The critical decision method13 is perhaps the most established CTA method. 
Data collected using this method are particularly valuable because they include a first-
person perspective in the context of challenging real-world scenarios.  Each participating 
urologist was asked to describe a case in which he or she used intravesical 
chemotherapy, and a case for which he or she did not, with an emphasis on cases that 
were not straightforward. Critical points about the case were then probed to explore 
elements such as goals, options, use of cues, and specific contextual elements 
considered during the case. Each interview was digitally audio-recorded. 
Data Collection and Analysis:  
 The Indiana University Institutional Review Board approved the study prior to 
data collection.  Interviews were conducted from August 2017 to May 2018.   After each 
interview, the recordings were transcribed and housed in a password-protected Dedoose 
software database. (Version 8.2.14, Los Angeles, CA)  Following each interview, the 
research team met to review field notes and develop analytic memos to highlight 
interview findings.  After the interviews were transcribed, two researchers independently 
coded the interview segments and identified provisional themes. A codebook listing each 
theme and its description was created. (Appendix 2).  Codes representing the themes 



















 Demographics of the participants are detailed in Table 1. The median age of 
those interviewed was 44 years; nearly all were white (92%), most were male (84%), 
and most (69%) had been in practice for 10 years or less. About a third (30%) had 
fellowship training beyond residency.  The main clinical settings represented were 
academia (15%), private practices with more than 8 urologists (62%), and hospital-
employed urologists (23%). 
Emergent themes 
Workflow processes  
 Workflow was identified as a broad theme that was subdivided into categories of 
ordering, instilling, and draining the drug from the bladder. Of these, instilling the drug 
was the most straightforward, and no barriers were identified related to this portion of 
mitomycin C use. Experience with ordering and draining mitomycin C varied by 
institution and seemed largely related to the volume of cases seen at each site. Table 2 
details challenges described by participants across the thematic categories.   
 Ordering the drug. At surgery sites with fewer procedures, ordering mitomycin C 
was often more problematic. As one participant noted “[I] tried to figure out how to put it 
in the computer system and couldn’t figure it out.  I told the nurse to give her 40mg, and 
then the pharmacist called me to confirm the dose.”  This example also highlights issues 
related to ordering the drug category, specific to each site’s electronic health record 
system.  One participant stated that when he “logged into the electronic medical record, I 
could not find the order, so I had to call the pharmacist who had to page the 
chemotherapy pharmacist.”  Breakdowns in communication such as these delayed care 
















Several participants reported a more streamlined process in which they listed 
mitomycin C as a note embedded in the operating room schedule. This alerted the 
pharmacist for the case to prepare the drug before the case began on the same day as 
the procedure.  This strategy allowed the physician to have the drug immediately 
available in the operating room if everything went according to plan.   
There were also tensions about when to order the drug, to avoid wasting it.  If 
ordered too soon and there was a bladder perforation, then the drug would be wasted.  
Conversely, if it were mixed later during the procedure, then the urologist would likely 
have to wait to receive the medication from pharmacy.  This tension was evidenced by 
one of the participants stating, “sometimes it takes an hour to get the stuff, so it just 
depends on...I probably could do a better job of pre-ordering it, but they don't like to mix 
it if you don't know you're going to use it.” 
Draining the drug from the bladder. At some sites, the lack of established 
protocols for postoperative care and limited chemotherapeutic training of recovery-room 
nurses led to frustration for physicians. In some cases, the urologist was called back to 
the recovery room to drain the drug from the bladder after s/he had moved to another 
patient. Participants at some sites noted a lack of recovery-room nurse training, 
sometimes resulting in confusion about how to dispose of the medication. One 
participant stated, “you get a lot of push-back from PACU nurses who do not want to 
give that medication... so they really encourage us to do it in the operating room, so that 
can be kind of a delay as well”.  Another participant stated, “generally phone calls have 
been an issue”, regarding how to drain it or properly dispose of it. 
Additional issues unique to delivery of this medication were how it differs from 
other medications administered in the operating room.  For example, the pharmacist 
mixes mitomycin C on the day of the procedure. The drug expires relatively quickly and 
















requires a chemical safety hood, which isn’t routinely available in the smaller operating 
room pharmacies, necessitating mixing the drug at a larger hospital pharmacy and 
transporting it to the operating room where the surgery is taking place.  
Urologists’ fears of pharmacologic side effects  
  Several participants expressed a noticeable reluctance to use mitomycin C 
following a TURBT.  Considering use of the drug appeared to create some anxiety, as 
evidenced by one participant when asked, “Did this patient have any trouble [side effects 
of mitomycin]?” The urologist responded, “no, neither one of them did....Thank God.”  
This statement hints that the participant did not feel confident that mitomycin C could be 
used reliably without significant side effects from the treatment.  Participants expressed 
an uncertain “trust” of the drug, and concern about potential side effects. One stated, 
“There was no perforation or anything, but he had a horrible reaction... like chemical 
cystitis with a lot of pelvic pain.”   A similar experience led another participant to state, “It 
made me feel like the treatment was worse than the disease. The net result of the 
participants’ experience was to question whether the benefits of using mitomycin C 
outweighed the risks, with many favoring the more conservative approach not to use the 
drug. 
 Nearly all participants had known about an individual patient or a small number of 
patients who had experienced significant side effects from the drug, including cystitis, 
dysuria, or pelvic pain. The low frequency of adverse events had a disproportionately 
large effect on participants’ understanding of the risks involved in using the drug. As 
noted by one participant, “[One patient]… ended up losing his kidney, and he’s had to 
have two procedures now.... and the whole thing was a nightmare.  ...if it had only been 
the one time, then okay, but then my partner... told me about that other perforation with 
















side effects seemed to outweigh the evidence-based potential benefit of reduced 
recurrence of bladder cancer. 
Identifying patients most likely to benefit  
 As the participants recalled specific cases during the interviews, it was clear that 
there was general agreement about which patients would benefit most from its use.  For 
example, most indicated that patients with “small papillary tumors”, “recurrent tumors”, 
and “no perforation of [the] bladder” were most likely to benefit.  Similarly, most reported 
that they would not use the medication for “large sessile tumors”, for “larger resection 
beds in the bladder”, or when there was increased risk of perforation due to a deep 
resection of the bladder during the surgery.  There were a few exceptions in which 
participants described misconceptions and uncertainty about when the drug is most 
likely to be effective. For example, one participant believed that mitomycin C would be 
most effective in high-grade but not low-grade tumors.  Additionally, two participants 
used the drug only after multiple recurrences of bladder cancer within a period of 6-12 
months.   
Three of the 13 participants mentioned clinical details that they believed were 
relevant to a decision about mitomycin C, but that the research team believed were not 
relevant according to available medical knowledge and evidence about when to use the 
medication. 15  Table 3 is a “knowledge table” of participants’ appropriate and 


















 This study focused on understanding urologists’ perspectives grounded in guided 
interviews about actual patients. We identified a number of complexities involved in 
deciding about, and using, mitomycin C in an intraoperative setting. There were 
influential workflow processes such as proper order entry to avoid delay in care, timely 
mixing of the medication in the pharmacy, proper postoperative nursing knowledge 
about disposal of the drug, and individual characteristics that influenced willingness to 
give the medication based on experiences and fear of side effects. 
 Our findings expand on others’ work that acknowledges that some physicians 
never offer this recommended medication to their patients.  One study reported 67% of 
urologists never used intraoperative intravesical chemotherapy, but reasons for this 
approach have never been detailed.10 Our study indicates that the workflow associated 
with administering mitomycin C is often too complex and time-consuming to justify using 
the drug. Furthermore, fear of side effects—some based on experience of the 
participants or their colleagues—presented as an insurmountable barrier for some, 
despite the low frequency of adverse effects among the population.  The recent 
randomized SWOG S0337 trial data suggests that perhaps gemcitabine in this setting 
may temper some of these fears of chemical cystitis seen with mitomycin C.16 In this 
trial, the risk of grade 3 toxicities was low with gemcitabine (2.4%) and also low with 
saline (3.4%). In addition, no grade 4 or 5 toxicities were noted.  This may result in 
higher utilization of gemcitabine in the immediate postoperative setting, but this would 
overcome only one of the barriers found in our study.  While cost was not specifically 
addressed in this study, one may also assume the cheaper cost of gemcitabine 
















possible concerns of mixing the medication early before the surgery begins only to have 
to waste the drug if a bladder perforation occurred during the procedure. 
 This study is limited by its small sample size.  The reproducibility and 
generalizability of our findings are, therefore, uncertain.  The sampling was initially 
aimed to be purposeful, but due to low response rates to mailed invitations, convenience 
sampling was used instead.  The effect, if any, of sampling on outcomes is unknown. 
However, the urologists sampled covered a wide geographic area within the state of 
Indiana and were trained in a variety of residency programs across the country.  Over 
50% of participants did received their medical school degrees from Indiana University.  
Despite the limited geographic sampling due to funding constraints, the diverse 
residency training background of participants may reduce this potential limitation.  It is 
also worth noting that the study lacks the input of additional stakeholders, such as 
nurses, pharmacists, and patients, who were involved in the care. 
 These limitations notwithstanding, the findings establish a model upon which to 
build in creating interventions to improve adoption and effectiveness. Additionally, this is 
the first qualitative exploratory study to provide first-person perspective, context, and 
insight, which a survey or large administrative dataset is unable to provide.   
 In summary, moving from efficacy to effectiveness requires understanding the 
context and environment in which the drug is going to be used.  To date, investigators 
have seemingly not paid enough attention to the complexities we have uncovered in this 
study and may explain why the drug, despite its efficacy, has not been effectively used. 
Future directions of research will be to develop, test, and refine interventions targeting 
the workflow process that would assist with efficient ordering, instilling, efficient drainage 
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Median Age (IQR) 44 (40-48) 










Gender N (%) 





















Fellowship training N (%) 









Type of Urology practice N (%) 
• Academic 
• Private practice (>8 urologists) 















































Location most commonly performing TURBTs 
• Hospital only 























Table 2. Barriers and Facilitators to Workflow for postoperative chemotherapy* 





put on OR 
schedule 
• Should be 
part of preop 
checklist 
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and thus 
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• Generally a 
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• At times when 
delayed, 
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to instill it 
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done in OR, 
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and 
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it (seems not 
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Table 3. Correct and Incorrect Physician responses identifying patients thought most likely to 
benefit from postoperative chemotherapy.  
Correct non-use mitomycin C: Correct use mitomycin C: Incorrect use of 
mitomycin C 
• Invasive 
• High Grade 
• Perforation 
• Clearly sessile tumor 
• Sessile high grade 
• Large papillary tumor 
• Large surface area 
• Extensive resection into 
the muscle 
• Extensive resection into 
the fat 
• Bulky tumor 
• Patient bleeding 
• Loss of integrity of bladder 
wall 
• Has had recurrence 
>1yr 
• Any low-grade tumor 
• Multi-focal low grade 
• High grade 
tumors 
• Multiple quickly 
recurring tumors  
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